Luteolin

Luteolin

SCHEMBL4729034

O=c1cc(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12.O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12

nearest known ligand 0.92

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLH Q9Y253 8/20 0.92
MEN1 O00255 8/20 0.92
KMT2A Q03164 8/20 0.92
MAPT P10636 7/20 0.92
ALDH1A1 P00352 6/20 0.92
CYP1A1 P04798 6/20 0.92
CYP1A2 P05177 6/20 0.92
CYP3A4 P08684 6/20 0.92
CYP1B1 Q16678 6/20 0.92
ABCB1 P08183 5/20 0.92
KDM4E B2RXH2 5/20 0.92
HSD17B10 Q99714 5/20 0.92
CYP2C9 P11712 5/20 0.92
CYP2C19 P33261 5/20 0.92
IP6K2 Q9UHH9 5/20 0.92
HPGD P15428 4/20 0.92
FTO Q9C0B1 4/20 0.92
XDH P47989 4/20 0.92
HDAC6 Q9UBN7 4/20 0.92
TP53 P04637 4/20 0.92

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Luteolin SCHEMBL29352380 0.96 POLH (1.00) POLHMEN1KMT2AMAPTALDH1A1
Luteolin SCHEMBL30045580 0.96 POLH (1.00) POLHMEN1KMT2AMAPTALDH1A1
Luteolin SCHEMBL28256564 0.96 POLH (1.00) POLHMEN1KMT2AMAPTALDH1A1
Luteolin SCHEMBL29376494 0.96 POLH (1.00) POLHMEN1KMT2AMAPTALDH1A1
Luteolin SCHEMBL20426 0.96 POLH (1.00) POLHMEN1KMT2AMAPTALDH1A1
Luteolin SCHEMBL31542150 0.94 POLH (0.97) POLHMEN1KMT2AMAPTALDH1A1
Luteolin SCHEMBL31168048 0.94 POLH (0.97) POLHMEN1KMT2AMAPTALDH1A1
Luteolin SCHEMBL31539190 0.94 POLH (0.97) POLHMEN1KMT2AMAPTALDH1A1
Luteolin SCHEMBL31678931 0.94 POLH (0.97) POLHMEN1KMT2AMAPTALDH1A1
Luteolin SCHEMBL1659262 0.94 POLH (0.97) POLHMEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080268024-A1 Compositions for Oral and/or Topical Administration COGNIS IP MANAGEMENT GMBH (DE) 2008-10-30 US claimed
WO-2024011228-A1 PLANT BASED HONEY COMPOSITION Melibio, Inc. (US) 2024-01-11 WO disclosed
CN-102579540-B Preparation method and application of sowthistle-leaf ixeris seedling flavonoid aglycone Shenyang shuangding pharmaceutical co ltd 2014-08-06 CN disclosed
CN-102579540-A Preparation method and application of sowthistle-leaf ixeris seedling flavonoid aglycone Shenyang shuangding pharmaceutical co ltd 2012-07-18 CN disclosed
CN-101249118-A Chinese medicine extract and medicine use thereof HU JUN (CN) 2008-08-27 CN disclosed
CN-101181319-A Chinese medicine and mass control method of preparations thereof HU JUN (CN) 2008-05-21 CN disclosed
WO-2008046521-A1 PREPARATION FOR ORAL ADMINISTRATION (II) COGNIS IP MANAGEMENT GMBH (DE) 2008-04-24 WO disclosed
WO-2008028585-A2 COSMETIC AND/OR PHARMACEUTICAL PREPARATIONS CONTAINING HOODIA EXTRACTS COGNIS IP MANAGEMENT GMBH (DE) 2008-03-13 WO disclosed
WO-2008028584-A1 PREPARATIONS FOR ORAL ADMINISTRATION (I) COGNIS IP MANAGEMENT GMBH (DE) 2008-03-13 WO disclosed
CN-101045072-A Extractive of turnipia arguta leaves and its pharmaceutical use HU JUN (CN) 2007-10-03 CN disclosed
CN-101011435-A Shanxiangyuan leaf extract, preparation method and uses thereof HU JUN (CN) 2007-08-08 CN disclosed
CN-101007030-A Quality control methods of leaves of cordyalis esquirolii and its preparation HU JUN (CN) 2007-08-01 CN disclosed
WO-2007068390-A1 PRE-MIXES FOR PERSONAL AND HOME CARE COMPOSITIONS COGNIS IP MANAGEMENT GMBH (DE) 2007-06-21 WO disclosed
WO-2005115170-A1 ORAL AND /OR TOPICAL COMPOSITIONS COGNIS IP MANAGEMENT GMBH (DE) 2005-12-08 WO disclosed
WO-2005053435-A1 PREPARATIONS FOR ORAL AND/OR TOPICAL APPLICATION COGNIS IP MANAGEMENT GMBH (DE) 2005-06-16 WO disclosed
WO-2005053721-A1 ANTIOXIDANT PREPARATION FOR ORAL AND/OR TOPICAL APPLICATION COGNIS IP MANAGEMENT GMBH (DE) 2005-06-16 WO disclosed
EP-0263553-A2 Method of inhibiting gene induction SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1988-04-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080268024-A1 Compositions for Oral and/or Topical Administration FABP2, FABP6, CUTA POLH 290/4885MEN1 2644/4885KMT2A 4465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.